Ipilimumab and Radiation in Patients with High-risk Resected or Regionally Advanced Melanoma.

ABSTRACT:

Purpose

In this prospective trial, we sought to assess the feasibility of concurrent administration of ipilimumab and radiation as adjuvant, neoadjuvant, or definitive therapy in patients with regionally advanced melanoma.

Patients and methods

Twenty-four patients in two cohorts were enrolled and received ipilimumab at 3 mg/kg every 3 weeks for four doses in conjunction with radiation; median dose was 4,000 cGy (interquartile range, 3,550-4,800 cGy). Patients in cohort 1 were treated adjuvantly; patients in cohort 2 were treated either neoadjuvantly or as definitive therapy.

Results

Adverse event profiles were consistent with those previously reported with checkpoint inhibition and radiation. For the neoadjuvant/definitive cohort, the objective response rate was 64% (

SUBMITTER: Salama AKS 

PROVIDER: S-EPMC8759408 | biostudies-literature | 2021 Mar

REPOSITORIES: biostudies-literature